SCHEMBL18361784

SCHEMBL18361784

CCCCCC(CN)n1nc(-c2ccc(Cl)cc2)cc1C(=O)OCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ TSHR P16473 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ POLB P06746 3/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ ALPL P05186 1/20 0.43
▸ FAAH O00519 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ IDO1 P14902 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TEAD2 Q15562 1/20 0.39
▸ ENPP2 Q13822 1/20 0.39
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18350252 0.88 CHRNA7 (0.40) SMN1; SMN2NPC1RAB9ATSHRALDH1A1
SCHEMBL18361797 0.83 FAAH (0.41) SMN1; SMN2NPC1RAB9ATSHRALDH1A1
SCHEMBL20681941 0.81 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9ATSHRALDH1A1
SCHEMBL16700446 0.80 TEAD2 (0.41) SMN1; SMN2NPC1RAB9ATSHRALDH1A1
SCHEMBL18350265 0.79 MEN1 (0.40) SMN1; SMN2NPC1RAB9ATSHRALDH1A1
SCHEMBL16700430 0.77 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1POLBTDP1LMNA
SCHEMBL2173892 0.76 TSHR (0.57) SMN1; SMN2NPC1RAB9ATSHRALDH1A1
SCHEMBL5022767 0.74 TSHR (0.58) SMN1; SMN2NPC1RAB9ATSHRALDH1A1
SCHEMBL16730921 0.74 SMN1; SMN2 (0.38) SMN1; SMN2NPC1RAB9AALDH1A1POLB
SCHEMBL18003909 0.74 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9ATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10189843-B2 Fused pyrazole derivative having autotaxin inhibitory activity THE UNIVERSITY OF TOKYO (JP) 2019-01-29 — — US disclosed
EP-3112369-A1 FUSED PYRAZOLE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY The University of Tokyo (JP) 2017-01-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189843-B2 Fused pyrazole derivative having autotaxin inhibitory activity ENPP2, PRTN3, TPX2 SMN1; SMN2 4197/4885NPC1 3328/4885RAB9A 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback